Apyx Medical Corporation, a maker of medical devices and supplies and the developer of Helium Plasma Technology, marketed and sold as Renuvion in the cosmetic surgery market and J-Plasma in the hospital surgical market, announces the publication of two separate peer-reviewed articles published in the journal, Dermatological Reviews.

“We are very pleased to announce these two peer-reviewed clinical publications, which represent important additions to the portfolio of clinical evidence supporting the use of Renuvion.

“Specifically, these publications looked retrospectively at the use of Renuvion when used independently of liposuction for subdermal coagulation in the neck and when used in combination with liposuction for subdermal coagulation in various treatment areas of the body.

“The data from the retrospective studies in these publications serves to strengthen the risk/benefit profile of Renuvion’s Helium Plasma Technology. Building on the results of these studies, we look forward to the continued expansion of our portfolio of clinical evidence to demonstrate the clinical utility of our Renuvion technology and facilitate broad-based adoption in the market.”

— Charlie Goodwin, President and Chief Executive Officer

The peer-reviewed clinical publications are:

A Retrospective Chart Review of Subdermal Neck Coagulation Using Helium Plasma Technology:

This journal article consisted of two separate retrospective chart review studies (Study 1, n=15 and Study 2, n= 13) performed using data from subjects who had undergone helium plasma treatment with Renuvion for subdermal coagulation to achieve tissue contraction in the neck.

Safety and Efficacy of Helium Plasma for Subdermal Coagulation:

This journal article consisted of two separate retrospective chart review studies (Study 1, n= 37 and Study 2, n= 148) performed using data from subjects who had undergone liposuction followed by subdermal coagulation using Renuvion. Subjects were treated in a variety of anatomical areas, such as the abdomen, arms, and neck.

[Source(s): Apyx Medical Corporation, Business Wire]

Related Content:
Apyx Medical Corp Receives Regulatory Clearance to Market and Sell Its Helium Plasma Technology Products in Five New Countries
Apyx Medical Corporation Announces Subject Enrollment Initiated in New Study Evaluating the Use of Renuvion Technology in Dermal Resurfacing Procedures
Apyx Medical Corporation Receives 510(k) Clearance for the Apyx Plasma/RF Handpiece